Cargando…
Effects of pirfenidone targeting the tumor microenvironment and tumor-stroma interaction as a novel treatment for non-small cell lung cancer
Targeting cancer-associated fibroblasts (CAFs), as well as the crosstalk between stroma and cancer cells, could be of value in managing cancers. Pirfenidone (PFD) is an anti-fibrotic agent for idiopathic pulmonary fibrosis. This study aimed to investigate the possibility that PFD might exert an anti...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7331721/ https://www.ncbi.nlm.nih.gov/pubmed/32616870 http://dx.doi.org/10.1038/s41598-020-67904-8 |
_version_ | 1783553389749075968 |
---|---|
author | Fujiwara, Ayako Funaki, Soichiro Fukui, Eriko Kimura, Kenji Kanou, Takashi Ose, Naoko Minami, Masato Shintani, Yasushi |
author_facet | Fujiwara, Ayako Funaki, Soichiro Fukui, Eriko Kimura, Kenji Kanou, Takashi Ose, Naoko Minami, Masato Shintani, Yasushi |
author_sort | Fujiwara, Ayako |
collection | PubMed |
description | Targeting cancer-associated fibroblasts (CAFs), as well as the crosstalk between stroma and cancer cells, could be of value in managing cancers. Pirfenidone (PFD) is an anti-fibrotic agent for idiopathic pulmonary fibrosis. This study aimed to investigate the possibility that PFD might exert an anti-tumor effect through inhibition of fibroblast activation and the tumor-stroma interaction in non-small cell lung cancer (NSCLC) cell lines in vitro and in vivo. PFD significantly inhibited myofibroblast differentiation and activation of both primary cultured normal human lung fibroblasts and CAFs. Cocultivation of NSCLC cells with conditioned media (CM) of fibroblasts changed the morphology or epithelial to mesenchymal transition (EMT) status, and PFD suppressed these changes. Cocultivation of CAFs with CM of NSCLC cells also induced activation of CAFs, and these changes were suppressed by PFD. On in vivo examination, CAFs promoted tumor progression, and PFD suppressed tumor progression with an inhibitory effect on tumor-stroma crosstalk. PFD might inhibit not only fibroblast activity, but also the crosstalk between cancer cells and fibroblasts. PFD may have great potential as a novel treatment for NSCLC from multiple perspectives. |
format | Online Article Text |
id | pubmed-7331721 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-73317212020-07-06 Effects of pirfenidone targeting the tumor microenvironment and tumor-stroma interaction as a novel treatment for non-small cell lung cancer Fujiwara, Ayako Funaki, Soichiro Fukui, Eriko Kimura, Kenji Kanou, Takashi Ose, Naoko Minami, Masato Shintani, Yasushi Sci Rep Article Targeting cancer-associated fibroblasts (CAFs), as well as the crosstalk between stroma and cancer cells, could be of value in managing cancers. Pirfenidone (PFD) is an anti-fibrotic agent for idiopathic pulmonary fibrosis. This study aimed to investigate the possibility that PFD might exert an anti-tumor effect through inhibition of fibroblast activation and the tumor-stroma interaction in non-small cell lung cancer (NSCLC) cell lines in vitro and in vivo. PFD significantly inhibited myofibroblast differentiation and activation of both primary cultured normal human lung fibroblasts and CAFs. Cocultivation of NSCLC cells with conditioned media (CM) of fibroblasts changed the morphology or epithelial to mesenchymal transition (EMT) status, and PFD suppressed these changes. Cocultivation of CAFs with CM of NSCLC cells also induced activation of CAFs, and these changes were suppressed by PFD. On in vivo examination, CAFs promoted tumor progression, and PFD suppressed tumor progression with an inhibitory effect on tumor-stroma crosstalk. PFD might inhibit not only fibroblast activity, but also the crosstalk between cancer cells and fibroblasts. PFD may have great potential as a novel treatment for NSCLC from multiple perspectives. Nature Publishing Group UK 2020-07-02 /pmc/articles/PMC7331721/ /pubmed/32616870 http://dx.doi.org/10.1038/s41598-020-67904-8 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Fujiwara, Ayako Funaki, Soichiro Fukui, Eriko Kimura, Kenji Kanou, Takashi Ose, Naoko Minami, Masato Shintani, Yasushi Effects of pirfenidone targeting the tumor microenvironment and tumor-stroma interaction as a novel treatment for non-small cell lung cancer |
title | Effects of pirfenidone targeting the tumor microenvironment and tumor-stroma interaction as a novel treatment for non-small cell lung cancer |
title_full | Effects of pirfenidone targeting the tumor microenvironment and tumor-stroma interaction as a novel treatment for non-small cell lung cancer |
title_fullStr | Effects of pirfenidone targeting the tumor microenvironment and tumor-stroma interaction as a novel treatment for non-small cell lung cancer |
title_full_unstemmed | Effects of pirfenidone targeting the tumor microenvironment and tumor-stroma interaction as a novel treatment for non-small cell lung cancer |
title_short | Effects of pirfenidone targeting the tumor microenvironment and tumor-stroma interaction as a novel treatment for non-small cell lung cancer |
title_sort | effects of pirfenidone targeting the tumor microenvironment and tumor-stroma interaction as a novel treatment for non-small cell lung cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7331721/ https://www.ncbi.nlm.nih.gov/pubmed/32616870 http://dx.doi.org/10.1038/s41598-020-67904-8 |
work_keys_str_mv | AT fujiwaraayako effectsofpirfenidonetargetingthetumormicroenvironmentandtumorstromainteractionasanoveltreatmentfornonsmallcelllungcancer AT funakisoichiro effectsofpirfenidonetargetingthetumormicroenvironmentandtumorstromainteractionasanoveltreatmentfornonsmallcelllungcancer AT fukuieriko effectsofpirfenidonetargetingthetumormicroenvironmentandtumorstromainteractionasanoveltreatmentfornonsmallcelllungcancer AT kimurakenji effectsofpirfenidonetargetingthetumormicroenvironmentandtumorstromainteractionasanoveltreatmentfornonsmallcelllungcancer AT kanoutakashi effectsofpirfenidonetargetingthetumormicroenvironmentandtumorstromainteractionasanoveltreatmentfornonsmallcelllungcancer AT osenaoko effectsofpirfenidonetargetingthetumormicroenvironmentandtumorstromainteractionasanoveltreatmentfornonsmallcelllungcancer AT minamimasato effectsofpirfenidonetargetingthetumormicroenvironmentandtumorstromainteractionasanoveltreatmentfornonsmallcelllungcancer AT shintaniyasushi effectsofpirfenidonetargetingthetumormicroenvironmentandtumorstromainteractionasanoveltreatmentfornonsmallcelllungcancer |